Clinical Rheumatology

, Volume 36, Issue 9, pp 2159–2162 | Cite as

Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

  • David Aguirre-Valencia
  • Iván Posso-Osorio
  • Juan-Carlos Bravo
  • Fabio Bonilla-Abadía
  • Gabriel J. Tobón
  • Carlos A. Cañas
Case Based Review


Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome (CSS), is a small vessel vasculitis associated with eosinophilia and asthma. Clinical manifestations commonly seen in patients presenting with EGPA range from upper airway and lung involvement to neurological, cardiac, cutaneous, and renal manifestations. Treatment for severe presentations includes steroids, cyclophosphamide, plasmapheresis, and recently, rituximab. Rituximab is associated with a good response in the treatment of vasculitis, but a variable response for the control of allergic symptoms. Here, we report a 16-year-old female patient with severe EGPA (gastrointestinal and cutaneous vasculitis, rhinitis and asthma) refractory to conventional treatment. She was treated with rituximab, which enabled rapid control of the vasculitis component of the disease, but there was no response to rhinitis and asthma. Additionally, she developed severe bronchospasm during rituximab infusion. Sequential rituximab and omalizumab were initiated, leading to remission of all manifestations of vasculitis, rhinitis, and asthma, in addition to bronchospasm related to rituximab infusion.


Churg-Strauss syndrome EGPA Eosinophilic granulomatosis with polyangiitis Omalizumab Rituximab 


Compliance with ethical standards




  1. 1.
    Unizony SH, Stone, JH (2015) 157- Antineutrophil cytoplasmic antibody–associated vasculitis. In: Silman AJ, Smolen JS, Weinblatt ME, Weisman M (eds) MHBTR, 6th edn. Elsevier Ltd., Philadelphia, pp 1310–1321Google Scholar
  2. 2.
    Greco A, Ida M, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G et al (2015) Autoimmunity reviews Churg–Strauss syndrome. Autoimmun Rev 14:341–348. doi: 10.1016/j.autrev.2014.12.004 CrossRefPubMedGoogle Scholar
  3. 3.
    Vaglio A, Moosig F, Zwerina J Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol 24:24–30. doi: 10.1097/BOR.0b013e32834d85ce
  4. 4.
    Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T et al (2016) (2012) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594. doi: 10.1136/annrheumdis-2016-209133 CrossRefPubMedGoogle Scholar
  5. 5.
    Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry M-J, Amudala N et al (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 75:396–401. doi: 10.1136/annrheumdis-2014-206095 CrossRefPubMedGoogle Scholar
  6. 6.
    Bouldouyre M-A, Cohen P, Guillevin L (2009) Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 68:606. doi: 10.1136/ard.2008.093773 CrossRefPubMedGoogle Scholar
  7. 7.
    Ramírez LF, Canas CA, Tobon GJ, Bonilla F, Serrano CD (2013) Successful desensitisation to rituximab in four patients with autoimmune diseases. Allergy Eur J Allergy Clin Immunol 68:211–212Google Scholar
  8. 8.
    Baldini C, Talarico R (2010) Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin N Am 36:527–543. doi: 10.1016/j.rdc.2010.05.003 CrossRefGoogle Scholar
  9. 9.
    Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sanchez-Menendez M, Ytterberg SR et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum 64:3770–3778. doi: 10.1002/art.34584 CrossRefPubMedGoogle Scholar
  10. 10.
    Jachiet M, Samson M, Cottin V, Kahn J-E, Le Guenno G, Bonniaud P et al (2016) Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol 68:2274–2282. doi: 10.1002/art.39663 CrossRefPubMedGoogle Scholar
  11. 11.
    Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S et al (2006) Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 117:1493–1499. doi: 10.1016/j.jaci.2006.02.028 CrossRefPubMedGoogle Scholar
  12. 12.
    Yong PFK, Malik R, Arif S, Peakman M, Amiel S, Ibrahim MAA et al (2009) Rituximab and omalizumab in severe, refractory insulin allergy. N Engl J Med 360:1045–1047. doi: 10.1056/NEJMc0808282 CrossRefPubMedGoogle Scholar
  13. 13.
    Busse W, Spector S, Rosén K, Wang Y, Alpan O (2013) High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol 132:485–486.e11. doi: 10.1016/j.jaci.2013.02.032 CrossRefPubMedGoogle Scholar
  14. 14.
    Sánchez-Ramon S, Eguiluz-Gracia I, Rodríguez-Mazariego ME, Paravisini A, Zubeldia-Ortuno JM, Gil-Herrera J et al (2013) Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 23:190–196PubMedGoogle Scholar
  15. 15.
    Iglesias E, Camacho Lovillo M, Delgado Pecellin I, Lirola Cruz MJ, Falcon Neyra MD, Salazar Quero JC et al (2014) Successful management of Churg-Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case. Pediatr Pulmonol 49:E78–E81. doi: 10.1002/ppul.22884 CrossRefPubMedGoogle Scholar
  16. 16.
    Borekci S, Aydin O, Hatemi G, Gemicioglu B (2015) Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: a case report. Int J Immunopathol Pharmacol 28:134–137. doi: 10.1177/0394632015572567 CrossRefPubMedGoogle Scholar
  17. 17.
    Nazir S, Tachamo N, Fareedy SB, Khan MS, Lohani S (2017) Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ann Allergy Asthma Immunol 118:372–374.e1. doi: 10.1016/j.anai.2016.12.003 CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  • David Aguirre-Valencia
    • 1
  • Iván Posso-Osorio
    • 1
  • Juan-Carlos Bravo
    • 2
  • Fabio Bonilla-Abadía
    • 1
  • Gabriel J. Tobón
    • 1
    • 3
  • Carlos A. Cañas
    • 1
  1. 1.GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina TraslacionalFundación Valle del Lili and Univesidad IcesiCaliColombia
  2. 2.Pathology DepartmentFundación Valle del LiliCaliColombia
  3. 3.Immunology LaboratoryFundación Valle del LiliCaliColombia

Personalised recommendations